Investment Thesis
Ardent Health exhibits deteriorating operational efficiency with flat net income growth despite 6% revenue growth, coupled with negative operating cash flow of -$60.2M indicating unsustainable cash burn. Razor-thin profitability margins (2.5% net, 4.7% operating) combined with extremely poor capital returns (3% ROE, 0.8% ROA) and 39.2% EPS decline signal fundamental operational challenges that outweigh the current adequate balance sheet position.
Strengths
- Solid revenue growth of 6% YoY demonstrates market demand and business continuity
- Strong liquidity position with current ratio of 2.12x and $609.7M in cash reserves
- Moderate debt/equity ratio of 0.80x provides reasonable financial flexibility
Risks
- Critical negative operating cash flow of -$60.2M despite positive net income indicates earnings quality concerns and unsustainable operations
- Profitability deterioration with flat net income growth while revenue grew 6%, plus 39.2% EPS decline shows operational efficiency collapse
- Severely depressed returns on capital (ROE 3%, ROA 0.8%) indicate capital is being deployed inefficiently and destroying shareholder value
Key Metrics to Watch
- Operating Cash Flow - must return to positive territory; negative cash flow is unsustainable
- Net Income Growth - needs to accelerate above revenue growth rate to demonstrate operational improvement
- Operating Margin - current 4.7% must expand as revenue grows or the business model is broken
Financial Metrics
Revenue
1.6B
Net Income
39.9M
EPS (Diluted)
$0.28
Free Cash Flow
-60.2M
Total Assets
5.3B
Cash
609.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
4.7%
Net Margin
2.5%
ROE
3.0%
ROA
0.8%
FCF Margin
-3.8%
Balance Sheet & Liquidity
Current Ratio
2.12x
Quick Ratio
2.00x
Debt/Equity
0.80x
Debt/Assets
67.0%
Interest Coverage
N/A
Long-term Debt
1.1B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:02:05.082158 |
Data as of: 2026-03-31 |
Powered by Claude AI